Shanghai, China – March 15, 2023 – Everest Medicines (HKEX 1952.HK), a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative medicines and vaccines, today announced that it will report financial results for the full year ended December 31, 2022 and provide a business update on March 31, 2023. The Company will hold live conference calls in English and Mandarin on March 31, 2023, Beijing Time. 

The English session of the conference call will be held at 9:00 AM on March 31, 2023 Beijing Time (9:00 PM U.S. Eastern Time on March 30, 2023), and the Mandarin session of the conference call will be held at 11:00 AM Beijing Time on the same day (11:00 PM U.S. Eastern Time on March 30, 2023).

The conference calls can be accessed by the following links: 

For English Session: 

Time: 9:00 AM Beijing Time, Friday, March 31, 2023 

Pre-Registration Link:   https://www.acecamptech.com/eventDetail/60503323 

Webcast Link:  https://www.acecamptech.com/meeting_live/70504909/4090?event_id=60503323event_id=60503222 

Alternatively, participants may dial in to the conference call using below dial-in information: 

For Mandarin Session: 

Time: 11:00 AM Beijing Time, Friday, March 31, 2023 

Webcast Link: https://s.comein.cn/ANQw8 

Alternatively, participants may dial into the conference call using below dial-in information: 

The replay of English session will be available shortly after the call and can be accessed by visiting the Company’s website at http://www.everestmedicines.com. 

About Everest Medicines 

Everest Medicines is a biopharmaceutical company focused on developing, manufacturing and commercializing transformative pharmaceutical products and vaccines that address critical unmet medical needs for patients in Asian markets. The management team of Everest Medicines has deep expertise and an extensive track record from both leading global pharmaceutical companies and local Chinese pharmaceutical companies in high-quality discovery, clinical development, regulatory affairs, CMC, business development, and operations. Everest Medicines has built a portfolio of potentially global first-in-class or best-in-class molecules in the company’s core therapeutic areas of renal diseases, infectious diseases and autoimmune disorders. For more information, please visit its website at www.everestmedicines.com. 

For further information, please contact: 

Investor Relations:
Leah Liu, VP Corporate Affairs
Everest Medicines
IR@everestmedicines.com 

Media Enquiries:
Jing Yang, Everest Medicines
jing.yang@everestmedicines.com